In a squeaker, FDA AdComm votes for an OK of Cempra’s antibiotic
Cempra $CEMP just barely squeaked through an AdComm review for its proposed new antibiotic solithromycin on Friday, with a slim majority of 7 to 6 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
